Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension.: mTOR Inhibition in Pulmonary Hypertension

Abstract : Pulmonary artery (PA) smooth muscle cell (SMC) proliferation in pulmonary hypertension (PH) may be linked to dysregulated mammalian target of rapamycin (mTOR) signaling. The mTOR pathway involves two independent complexes, mTORC1 and mTORC2, which phosphorylate S6 kinase (S6K) and serine/threonine kinase (Akt), respectively, and differ in their sensitivity to rapamycin. Here, we evaluated rapamycin-sensitive mTOR substrates and PA-SMC proliferation in rats with monocrotaline (MCT)-induced PH (MCT-PH). Compared with cells from control rats, cultured PA-SMCs from MCT-PH rats exhibited increased growth responses to platelet-derived growth factor, serotonin (5-hydroxytryptophan), IL-1β, insulin-like growth factor-1, or fetal calf serum (FCS), with increases in phosphorylated (Ser-473)Akt, (Thr-308)Akt, glycogen synthase kinase (GSK)3, and S6K reflecting activated mTORC1 and mTORC2 signaling. Treatment with rapamycin (0.5 μM) or the Akt inhibitor, A-443654 (0.5 μM), reduced FCS-stimulated growth of PA-SMCs from MCT-PH rats to the level in control rats while inhibiting Akt, GSK3, and S6K activation. Neither the tyrosine kinase inhibitor, imatinib (0.1 μM), nor the 5-hydroxytryptophan transporter inhibitor, fluoxetine (5 μM), normalized the increased PA-SMC growth response to FCS. Rapamycin treatment (5 mg/kg/d) of MCT-PH rats from Day 21 to Day 28 markedly reduced phoshop (p)-Aky, p-GSK3, and p-S6K in PAs, and normalized growth of derived PA-SMCs. This effect was not observed after 1 week of imatinib (100 mg/kg/d) or fluoxetine (20 mg/kg/d). Rapamycin given preventively (Days 1-21) or curatively (Days 21-42) inhibited MCT-PH to a greater extent than did imatinib or fluoxetine. Experimental PH in rats is associated with a sustained proliferative PA-SMC phenotype linked to activation of both mTORC1 and mTORC2 signaling and is suppressed by rapamycin treatment.
Type de document :
Article dans une revue
American Journal of Respiratory Cell and Molecular Biology, American Thoracic Society, 2013, 48 (5), pp.568-77. 〈10.1165/rcmb.2012-0429OC〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00834120
Contributeur : Georges Guellaen <>
Soumis le : vendredi 14 juin 2013 - 11:30:53
Dernière modification le : jeudi 28 janvier 2016 - 01:06:29
Document(s) archivé(s) le : mardi 4 avril 2017 - 21:48:04

Fichiers

Manuscript_MCT_revision_clean_...
Fichiers produits par l'(les) auteur(s)

Identifiants

Collections

Citation

Amal Houssaini, Shariq Abid, Nathalie Mouraret, Feng Wan, Dominique Rideau, et al.. Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension.: mTOR Inhibition in Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology, American Thoracic Society, 2013, 48 (5), pp.568-77. 〈10.1165/rcmb.2012-0429OC〉. 〈inserm-00834120〉

Partager

Métriques

Consultations de la notice

235

Téléchargements de fichiers

39